Preserving Geriatric Muscle With an Osteoporosis Medication

ConditionOsteoporosis

Trial statusRecruiting

Trial phasePhase 4

Trial typeInterventional

Biological sexAll

Age65+

SponsorChrissy Kistler

About this trial

Our goal is to demonstrate efficacy of the novel agent Denosumab to improve or preserve muscle health, strength, mobility and function in frail older adults.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial design

Design model

Parallel

Treatments tested in this trial

Denosumab 60 MG/ML
Drug
Subjects to receive Denosumab 60mg SQ and Zoledronic acid placebo IV
Zoledronic Acid 5Mg/Bag 100Ml Infusion
Drug
Subjects to receive Zoledronic Acid 5mg IV and Denosumab placebo

Treatment groups

155 Participants

are divided into 2 treatment groups

Group A: DenosumabExperimental treatment 1 intervention

Group B: Zoledronic acidActive comparator 1 intervention

Trial outcomes

Primary outcomes

Knee extension strength change

The primary muscle strength outcome measure will be the peak muscle force generated by the dominant leg (same side as dominant hand) knee extensor muscles in the sitting position with the knee at 60 degrees of flexion.

Time frame

12 Months

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Chrissy Kistler

Lead sponsor

University of Pittsburgh

Sponsor institution

Source ClinicalTrials.gov

Apply now